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Abstract Hematuria is a common presenting complaint in
pediatric nephrology clinics and often has a familial basis.
This teaching article provides an overview of causes,
diagnosis, and management of the major forms of familial
hematuria, Alport syndrome, and thin basement membrane
nephropathy.
Keywords Hematuria . Alport syndrome .
Thin basement membrane nephropathy . Type IV collagen
Introduction
The typical pediatric nephrologist will evaluate hundreds, if
not thousands, of children and adolescents with hematuria
during the course of her or his career. The major forms of
familial hematuria, Alport syndrome and thin basement
membrane nephropathy (TBMN), together account for
approximately 30–50% of children with isolated glomerular
hematuria referred to pediatric nephrology clinics for
consultation [1–4]. The objectives of this teaching article
are to (1) assist pediatric nephrologists in recognizing
patients who may have familial forms of hematuria, (2)
suggest diagnostic approaches that can be used to confirm
familial hematuria and make specific diagnoses, and (3)
discuss the implications of a diagnosis of familial hematuria
for prognosis, reproductive counseling, and treatment.
What is familial hematuria?
For this article, familial hematuria is defined as a group of
genetic disorders of glomerular capillaries that are charac-
terized clinically by the onset of persistent hematuria during
childhood. Hematuria may be the presenting feature of
other heritable diseases, including polycystic kidney dis-
ease, hypercalciuria, and other forms of hereditary urolith-
iasis. This article will focuses on the major forms of
familial hematuria: Alport syndrome and TBMN. All
patients with Alport syndrome and about 50% of those
with TBMN have mutations in type IV collagen, the
predominant collagenous constituent of glomerular capil-
lary walls. Minor forms of familial hematuria include
Epstein and Fechtner syndromes, which arise from muta-
tions in nonmuscle myosin heavy chain IIA [5]. In these
autosomal dominant disorders, hereditary nephritis with
ultrastructural features that may be reminiscent of Alport
syndrome is associated with sensorineural deafness and
macrothrombocytopenia.
Genetics of familial hematurias
A brief review of the genetics of the familial hematurias
may be helpful at this point (Table 1). About 80% of those
with Alport syndrome have the X-linked form of the
disease (XLAS), which is caused by mutations in COL4A5,
the gene encoding the α5 chain of type IV collagen [α5
(IV)]. Autosomal recessive Alport syndrome (ARAS)
accounts for about 15% of affected individuals and arises
from mutations in both alleles of COL4A3 or COL4A4,
which respectively encode the α3(IV) and α4(IV) chains.
The remainder of those with Alport syndrome, about 5%,
has autosomal dominant Alport syndrome (ADAS) due to
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heterozygous mutations in COL4A3 or COL4A4. However,
the majority of those with heterozygous mutations of
COL4A3 or COL4A4 have a form of familial hematuria
that is usually nonprogressive: TBMN.
Clinical features of familial hematurias
Persistent microscopic hematuria is the hallmark of Alport
syndrome, occurring in 100% of boys and 95% of girls with
XLAS [6] and all boys and girls with ARAS. Typically, red
cells number in the tens to dozens, particularly in boys. Red
blood cell casts may or may not be observed. Episodic
gross hematuria is not unusual. Some affected boys and
girls exhibit nearly continuous gross hematuria. The onset
of hematuria in affected boys occurs during infancy. On
occasion, an affected boy presents with bloodstains in his
diaper. About 10–15% of children with XLAS have de
novo mutations. Consequently, the great majority of
affected children with XLAS have a parent with hematuria.
However, normal urinalyses in the parents of a child with
hematuria do not exclude a diagnosis of XLAS. XLAS is
unlikely if hematuria is found in the father of a boy with
hematuria but not his mother.
Each parent of a child with ARAS is a heterozygous carrier
of a mutation in COL4A3 or COL4A4. About 50% of these
carriers exhibit hematuria. Therefore, hematuria may be
found in both, one, or neither parent of a child with ARAS.
As TBMN is, with rare exceptions, a nonprogressive
disorder, a family history of dialysis or kidney transplan-
tation in a child with hematuria suggests a diagnosis of
Alport syndrome. When assessing the significance of a
family history of renal failure, the typical natural history of
Alport syndrome and the evolving epidemiology of chronic
kidney disease should be considered. For example, renal
failure in a young male relative has different implications
than renal failure in an older individual with type 2
diabetes. A family history of deafness should also raise
suspicion for Alport syndrome, but it should be kept in
mind that any individual whose deafness is due to Alport
syndrome will also exhibit renal involvement, and the
degree of hearing loss tends to parallel the severity of the
kidney disease. So, for example, deafness in an otherwise
healthy 65-year-old male relative is probably secondary to a
process other than Alport syndrome.
Deafness ultimately develops in 80% of males with
XLAS [7] and at least that percentage of boys and girls with
ARAS. However, detectable hearing loss is often absent
when children with Alport syndrome are first evaluated,
because the onset of measurable deficits in hearing typically
occurs in late childhood. Hearing loss associated with
Alport syndrome has several consistent characteristics: it is
not present at birth; it is bilateral, with symmetrical onset
and severity; it initially involves high-frequency wave-
lengths; and gradually extends into conversational speech
over time. Consideration of these features of the Alport
hearing defect can help prevent the clinician from being led
down the wrong diagnostic path when presented with a
child who has renal disease and deafness.
About 40% of males with XLAS exhibit characteristic
ocular anomalies [7]. A distinctive maculopathy consisting of
whitish or yellowish flecks distributed around the macula
occurs in approximately 20% of XLAS males [7]. These
perimacular flecks increase in number with age [8] and are
most likely to be observed by an experienced ophthalmol-
ogist on dilated exam. Anterior lenticonus, the protrusion of
the central area of the lens into the anterior chamber, is
pathognomonic of Alport syndrome and occurs in about
20% of affected males with XLAS [7]. Anterior lenticonus is
typically discovered during adolescence or young adulthood.
A particularly bothersome problem is recurrent corneal
erosion, resulting in acute, severe ocular pain [9]. The
maculopathy is found in about 15% of females with XLAS;
anterior lenticonus is rarely observed [6]. Patients with
ARAS can display the same ocular anomalies as those found
in XLAS patients [10].
Because TBMN is, according to our current understanding,
a renal-limited disorder, the presence of extrarenal abnormal-
ities such as deafness or ocular lesions in someone with
hematuria makes a diagnosis of TBMN unlikely. The absence
of such findings does not, however, rule out Alport syndrome,
especially in the young patient.
In a small number of families, XLAS is associated with
smooth-muscle tumors, or leiomyomata, of the esophagus,
tracheobronchial tree and, in females, the external genitalia
[11]. The Alport syndrome diffuse leiomyomatosis complex
is a contiguous gene syndrome resulting from deletions
involving the adjacent COL4A5 and COL4A6 genes on the X
chromosome [12].
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Renal histology in familial hematurias
Alport syndrome and TBMN may be indistinguishable
from each other by routine light and immunofluorescence
microscopy, and by electron microscopy, in children.
Whereas males with Alport syndrome will eventually
exhibit light microscopy abnormalities, females may have
normal-appearing kidneys by light microscopy, as with
individuals with TBMN. In children with familial hematu-
ria, the presence of mesangial proliferation or focal
segmental glomerulosclerosis on light microscopy suggests
a diagnosis of Alport syndrome.
Since the early 1970s, electron microscopy has been an
important technique for diagnosing both TBMN and Alport
syndrome and for differentiating the two conditions in
patients with hematuria. Individuals with TBMN display
diffuse glomerular basement membrane (GBM) thinning
associated with attenuation of the lamina densa. The
endothelial and epithelial aspects of GBM are smooth and
regular, and podocyte foot processes are intact. GBM
attenuation is also the earliest glomerular abnormality in
patients with Alport syndrome. As a result, TBMN and
Alport syndrome may not be distinguishable by electron
microscopy in young children.
The pathognomonic ultrastructural lesion of Alport syn-
drome consists of (1) thickening of the GBM; (2) splitting of
the lamina densa into multiple strands that enclose electron-
lucent areas, which may contain electron-dense particles; (3)
scalloping of the epithelial aspect of the GBM; and (4) partial
to complete disappearance of podocyte foot processes in
regions of GBM thickening [13]. In males with XLAS, these
changes typically first appear during childhood, and the
extent of GBM displaying these alterations increases
progressively with age [14]. In females, the extent of GBM
thickening ranges from focal to diffuse, and the impact of
aging on GBM thickening is unpredictable.
Immunostaining of kidney and skin biopsy specimens
using monospecific antibodies against type IV collagen
chains is a valuable diagnostic modality in patients with
hematuria. The utility of this approach derives from the
effects of mutations in COL4A3, COL4A4, and COL4A5
genes on expression of α3(IV), α4(IV), and α5(IV) chains
in basement membranes. The α3(IV) and α4(IV) chains
exist in basement membranes in a single construct: the
α3α4α5(IV) heterotrimer. In the normal kidney, the
α3α4α5(IV) trimer is present in GBM, Bowman’s capsules,
and the basement membranes of distal tubules. Mutations in
both alleles of COL4A3 or COL4A4 in ARAS patients
frequently result in complete absence of α3α4α5 trimers
from renal as well as ocular and cochlear basement
membranes [15–17]. The α5(IV) chain participates in two
trimeric species: the aforementioned α3α4α5(IV) trimer and
the α5α5α6 (α52α6) trimer. In the kidney, α52α6 trimers
are normally found in Bowman’s capsules, distal and
collecting tubule basement membranes, and epidermal
basement membranes. Hemizygous COL4A5 mutations in
males with XLAS usually lead to elimination of both
α3α4α5 and α52α6 trimers from all basement membranes.
COL4A3 and COL4A4 mutations do not affect the expres-
sion of α52α6 trimers, however.
How can this information be applied to diagnosis of
hematuria? In many cases, consideration of type IV collagen
immunostaining results can lead to definitive diagnoses:
1. XLAS: In about 80% of males with XLAS, renal
basement membranes exhibit complete absence or, at
times, markedly diminished immunostaining for α3,
α4, and α5(IV) chains, and epidermal basement
membranes are negative for α5(IV) chains [18, 19].
About 60–70% of heterozygous females display mosaic
staining of renal basement membranes for α3, α4, and
α5(IV) chains and of epidermal basement membranes
for α5(IV) chains [20, 21]. Clearly, normal immuno-
staining results cannot exclude a diagnosis of XLAS.
2. ARAS: In many patients with ARAS, GBM is
completely negative for α3, α4, and α5(IV) chains
[22]. However, Bowman’s capsules and distal and
collecting tubules remain positive for α5(IV), because
in those basement membranes, α5(IV) is present in the
form of α52α6 trimers. For the same reason, epidermal
basement membranes also remain positive for α5(IV).
3. TBMN: Immunostaining for type IV collagen is normal
in kidneys and skin of subjects with TBMN. As noted
above, normal type IV collagen immunostaining does
not exclude Alport syndrome. However, normal type
IV collagen immunostaining supports a diagnosis of
TBMN in those with hematuria, normal urine protein
excretion, negative family history of renal failure, and
diffuse GBM thinning. Patients with autosomal domi-
nant Alport syndrome also exhibit normal immuno-
staining of skin and kidney for type IV collagen chains.
Molecular diagnosis of familial hematurias
The COL4A3, COL4A4, and COL4A5 genes have been
completely sequenced. Although the genes are large,
mutation detection rates in patients with XLAS and ARAS
are high [23–25]. Access to laboratories offering type IV
collagen gene analysis varies from country to country.
Molecular approaches may eventually supersede histolog-
ical methods for diagnosis of familial hematurias but, for
now, renal biopsy and skin biopsy are the tools most
clinicians rely upon for diagnosing these conditions.
Current information regarding molecular testing for Alport
Syndrome can be obtained at www.genereviews.org.
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Renal transplantation in Alport syndrome
In general, patients with Alport syndrome have good
transplant outcomes, with graft survival rates comparable
with those of patients with congenital urinary tract
anomalies [26]. Transplant preparation and posttransplant
care are the same for Alport patients, with two important
exceptions: First, planning for transplantation requires
special care to insure that affected family members are not
inadvertently allowed to serve as kidney donors. Donor
selection in Alport families is based on a thorough
understanding of disease genetics and is discussed in detail
in a recent review [27]. The dilemma most frequently
encountered during transplant planning for Alport patients
involves the decision about whether to allow a heterozy-
gous female with XLAS to donate a kidney to an affected
male relative. Because females with XLAS are at signifi-
cant risk for developing end-stage renal disease (ESRD)
late in life, kidney donation should be discouraged,
especially in those younger than 45 years of age [6, 28].
Following transplantation, care providers must maintain
a high degree of suspicion for posttransplant anti-GBM
nephritis as a cause of allograft dysfunction, especially in
the first year [27]. Posttransplant anti-GBM nephritis
affects about 3–5% of transplanted Alport males, and
usually results in rapid allograft destruction despite aggres-
sive therapy [27]. Surveillance for posttransplant anti-GBM
nephritis combines routine measures, such as frequent
measurement of serum creatinine and a low threshold for
performing an allograft biopsy, with serial monitoring for
circulating anti-GBM antibodies by enzyme-linked immu-
nosorbent assay (ELISA). It should be noted that a negative
anti-GBM ELISA result does not rule out posttransplant
anti-GBM nephritis [29], because the commercial ELISA
assays are relatively insensitive to anti-α5(IV) antibodies,
which make up the bulk of anti-GBM antibodies in patients
with posttransplant anti-GBM nephritis [30].
Management of familial hematurias
Results of studies in transgenic mice and in dogs with
Alport syndrome suggest that interference with the gener-
ation or action of angiotensin II may slow progression to
ESRD [31–33]. However, it must be cautioned that the
murine studies may be confounded by strain effects [34],
and there have been no controlled studies of angiotensin
blockade in human Alport subjects [35]. Uncontrolled
studies suggested that cyclosporine might have therapeutic
benefit in Alport syndrome [36], but enthusiasm has been
dampened by a subsequent study indicating that cyclospor-
ine treatment might be associated with accelerated devel-
opment of interstitial fibrosis [37].
In the absence of data, administration of angiotensin
antagonists, such as angiotensin-converting enzyme (ACE)
inhibitors and angiotensin receptor blockers, alone or in
combination, to patients who have developed overt pro-
teinuria is a reasonable approach with relatively little
capacity for harm. A recent uncontrolled study reported
that addition of an aldosterone inhibitor may augment the
effect of angiotensin blockade on proteinuria in children
with Alport syndrome [38].
Although patients given a diagnosis of TBMN do not
need treatment, they should not be lost to follow-up. A
reasonable approach would consist of annual urinalysis and
blood pressure measurement. As long as blood pressure and
urine protein excretion remain in the normal range, no
further evaluation is necessary.
Diagnostic approach
Alport syndrome and TBMN should be in the initial
differential diagnosis of all children and adolescents who
present with hematuria. Diagnostic criteria for Alport
syndrome and TBMN are presented in Table 2.
In general, any child whose hematuria does not clearly
localize to the lower urinary tract may have familial
hematuria. A careful family history aimed at identifying
relatives with known hematuria, kidney failure, or deafness
is an essential feature of the evaluation of children with
hematuria. However, it must be remembered that a negative
family history does not exclude Alport syndrome or
TBMN. It is also useful to screen all members of the
child’s immediate family (parents and siblings) for hema-
turia, as people with microscopic hematuria may not know
they have it.
Does every child with glomerular hematuria need a
kidney biopsy, or skin biopsy? The answer is “probably
not”. A child with dominantly inherited, isolated glomerular
hematuria and a negative family history of kidney failure
may be given a tentative diagnosis of TBMN and followed
expectantly. In a family with a well-established diagnosis of
Alport syndrome, children with hematuria may be pre-
sumed to be affected, although it is the author’s practice to
obtain a renal ultrasound in every affected child to exclude
a structural abnormality of the urinary tract that could affect
prognosis.
Skin biopsy with immunostaining for the α5(IV) chain is
particularly useful when suspicion of XLAS is high. Exam-
ples include a child with hematuria and a positive family
history of hematuria and kidney failure, or a child with
hematuria and sensorineural deafness. An algorithm incorpo-
rating skin biopsy, kidney biopsy and selective use of
molecular diagnostic methods is presented in Fig. 1. When
XLAS is just one of several possible diagnoses, for example
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in a child with hematuria and negative family history, a
kidney biopsy is more likely to yield a specific diagnosis.
Molecular diagnosis is likely to play a burgeoning role in
the diagnostic evaluation of hematuria, although access and
expense are still important limitations to this approach. The
importance of very early diagnosis may increase if it can be
shown that very early pharmacologic intervention can
modify the natural history of Alport syndrome. Molecular
diagnosis would be ideal for this purpose, although skin
and kidney biopsy are also applicable.
Table 2 Diagnostic criteria for familial hematurias
Alport syndrome
The presence of two of the following diagnostic criteria establishes the diagnosis of Alport syndrome:
Family history of hematuria progressing in males to ESRD
• About 10–15% of males with XLAS have de novo mutations, so family history may be negative for renal disease. Family history may also be
negative in patients with ARAS, although one or both parents may have hematuria
Characteristic thickening of the glomerular basement membrane and splitting of the lamina densa, detected by electron microscopy of kidney
biopsy specimens
• Children with Alport syndrome may exhibit only diffuse GBM attenuation, making differentiation from TBMN a challenge
Progressive, high-frequency sensorineural deafness
The hearing deficit is frequently detectable by audiometry in later childhood (5–10 years of age) in boys with XLAS and both boys and girls
with ARAS
Anterior lenticonus or perimacular retinal flecks
• These changes are pathognomonic of Alport syndrome. Anterior lenticonus is usually not detectable until later adolescence
Characteristic abnormalities of renal basement membrane expression of type IV collagen α3, α4, and α5 chains (i.e. the α3α4α5 network) by
immunostaining of renal biopsy specimens
• It is important to note that normal renal basement membrane expression of type IV collagen α3, α4, and α5 chains cannot by itself exclude a
diagnosis of Alport syndrome
• XLAS: about 80% of XLAS males exhibit complete absence of α3, α4, and α5 chains in renal basement membranes; 60–70% of XLAS
females exhibit mosaic staining patterns for these proteins
• ARAS: the characteristic pattern is complete absence of α3, α4, and α5 chains in GBM, absence of α3 and α4 chains in Bowman’s capsules
and distal tubule basement membranes, but persistence of α5 chains in Bowman’s capsules and distal tubule basement membranes (as a
component of α5α5α6 networks)
• ADAS: results of immunostaining for α3, α4, and α5 chains are normal
Characteristic abnormalities of epidermal basement membrane expression of the α5 chain of type IV collagen by immunostaining of skin biopsy
specimens
• The normal epidermal basement membrane expresses α5α5α6 networks. The α3α4α5 network is not expressed in epidermal basement
membranes of normal subjects
• It is important to note that normal epidermal basement membrane expression of the α5 chains cannot by itself exclude a diagnosis of Alport
syndrome
• XLAS: about 80% of XLAS males exhibit complete absence of α5 chains in epidermal basement membrane; 60–70% of XLAS females
exhibit mosaic staining patterns for this protein
• ARAS and ADAS: results of immunostaining for the α5 chain in epidermal basement membrane are normal
Mutations in COL4A3, COL4A4, or COL4A5 genes
• XLAS: the rate of detection of mutations in COL4A5 in males with XLAS is 80–90% by direct sequencing
• ARAS: direct sequencing identifies ∼90% of mutations in COL4A3 or COL4A4 in ARAS patients with consanguineous parents
Thin basement membrane nephropathy
A diagnosis of TBMN can be made on the basis of clinical and pedigree data; renal biopsy may be unnecessary. Criteria for a clinical diagnosis of
TBMN include all of the following criteria:
Isolated hematuria; kidney function, urine protein excretion, and blood pressure are normal
Positive family history of hematuria, consistent with autosomal dominant transmission
Negative family history of kidney failure
Renal biopsy may be used to confirm a suspected diagnosis of TBMN. Histological diagnosis is based upon the finding of diffuse attenuation of
GBM, as determined by electron microscopy, and the absence of other abnormalities by light microscopy (glomerular cellular proliferation or
glomerulosclerosis), immunofluorescence microscopy (glomerular deposition of immunoglobulin or complement), or electron microscopy
(lamina densa splitting or fusion of glomerular visceral epithelial cell foot processes). Diffuse GBM attenuation is present when mean GBM
width is greater than 2 SD below age- and gender-specific mean values.
Immunostaining of renal biopsy specimens for type IV collagen chains can provide useful adjunctive data. In a patient with diffuse GBM
attenuation and who satisfies clinical criteria for TBMN, normal immunostaining for type IV collagen α3, α4, and α5 chains (i.e. the α3α4α5
network) supports a diagnosis of TBMN.
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Summary
An early and accurate diagnosis in children with familial
hematuria provides important information for genetic
counseling, allays unnecessary anxiety in those with
TBMN, and identifies those who may benefit from
intervention. Careful assessment of clinical findings, ped-
igree data, and results of tissue studies allow accurate
diagnosis in the majority of patients. Wider availability of
molecular diagnosis would increase diagnostic precision.
Questions (Answers appear following the reference list)
1. Alport syndrome is a disorder of
a. type I collagen
b. type II collagen
c. type IV collagen
d. type V collagen
e. type VI collagen







3. The hearing loss of Alport syndrome
a. is congenital
b. is conductive
c. initially affects high frequency sounds
d. resolves following successful renal transplantation
e. is an uncommon feature of the disease









α 5(IV) negative (boys) or 
mosaic (girls) 
α 5(IV) positive 
Evaluation may stop here or proceed to 
molecular diagnosis.  Present uses 
include identification of asymptomatic 
carriers and prenatal diagnosis.  Future 
uses may include prediction of prognosis 
and early identification of candidates for 
treatment. 
KIDNEY BIOPSY 











Fig. 1 Algorithm incorporating
skin biopsy, kidney biopsy,
and selective use of molecular
diagnostic methods
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d. 75%
e. 95%
5. A small percentage of transplanted Alport patients
develop
a. nephrotic syndrome
b. de novo membranous nephropathy
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